Pulmatrix Appoints John P. Hanrahan Chief Medical Officer.LEXINGTON, Mass. -- Pulmatrix Inc., a biotechnology company commercializing a broad new class of treatments for respiratory disease Noun 1. respiratory disease - a disease affecting the respiratory system respiratory disorder, respiratory illness adult respiratory distress syndrome, ARDS, wet lung, white lung - acute lung injury characterized by coughing and rales; inflammation of the , announced today the appointment of John P. Hanrahan, M.D., M.P.H., as Senior Vice President and Chief Medical Officer. Dr. Hanrahan will lead the Company's clinical development programs beginning with Phase II trials assessing the efficacy of Pulmatrix's lead product in the treatment and prevention of several different respiratory infectious diseases infectious diseases: see communicable diseases. . Dr. Hanrahan joins Pulmatrix from Sepracor where he most recently served as Executive Medical Director for Pulmonary products. During his six years with Sepracor he led clinical development activities for the asthma drug Levalbuterol and the COPD COPD chronic obstructive pulmonary disease. COPD abbr. chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) drug Arformoterol, through FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. approvals in 2005 and 2006 respectively. Dr. Hanrahan's responsibilities at Sepracor included leading worldwide clinical development of the entire portfolio of projects for pulmonary and internal medicine indications, and serving on the Respiratory and Internal Medicine Therapeutic Assessment teams in support of partnering and M&A activities. Prior to joining Sepracor, he held multiple leadership positions spanning clinical development and medical affairs at Boehringer-Ingelheim and Muro Pharmaceuticals. Dr. Hanrahan began his career at Harvard Medical School Harvard Medical School (HMS) is one of the graduate schools of Harvard University. It is a prestigious American medical school located in the Longwood Medical Area of the Mission Hill neighborhood of Boston, Massachusetts. as a full-time tenure-track faculty member in pulmonary and emergency medicine and researcher in pulmonary epidemiology, while holding corresponding hospital appointments at the Beth Israel Deaconess Medical Center Both an international and regional referral center, Beth Israel Deaconess Medical Center (BIDMC) in Boston, Massachusetts is a major teaching hospital of Harvard Medical School. It was formed out of the 1996 merger of Beth Israel Hospital (founded in 1916) and . Dr. Hanrahan commented, "Pulmatrix's innovative therapies show revolutionary promise to meaningfully impact the transmission and occurrence of respiratory infections. I am truly excited to join the team and help guide the clinical development programs." Pulmatrix Chief Executive Officer Bob Connelly added, "This Company could fundamentally alter the therapeutic landscape for many respiratory diseases, and offer practical options to treat and prevent infection by a wide array of airborne pathogens. John comes to us at a perfect time with an ideal background in pulmonary medicine and public health, combined with a successful track record of advancing respiratory products through the clinic." About Pulmatrix Pulmatrix is a clinical stage biotechnology company developing a new class of inhaled therapies that treat, prevent, and help control the spread of respiratory infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. . The Company's novel pathogen independent approach utilizes the inherent properties of the airway and immune system immune system Cells, cell products, organs, and structures of the body involved in the detection and destruction of foreign invaders, such as bacteria, viruses, and cancer cells. Immunity is based on the system's ability to launch a defense against such invaders. to enable a single affordable product to combat a broad spectrum of viral and bacterial infections, without the development of resistance. The Pulmatrix approach is based on the ground-breaking scientific work of renowned Harvard Professor David Edwards David Edwards may refer to one of the following persons.
|
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion